4502 Takeda Pharmaceutical
- 4172.0
- +14.0+0.34%
Takeda Pharmaceutical News
Takeda Pharmaceutical: Annual Securities Report for the period from April 1, 2023 to March 31, 2024 (Fiscal year 147)
Takeda Pharmaceutical: Confirmatory letter.
Takeda Pharmaceutical: Internal Control Report - Period 147 (2023/04/01-2024/03/31)
Takeda Pharmaceutical: Financial Report - 147th Term (2023/04/01 - 2024/03/31)
Takeda Pharmaceutical: Takeda Pharmaceutical announces new board of directors appointment.
Takeda Pharmaceutical: About the decision regarding the allocation of directors' responsibilities.
Takeda Pharmaceutical: Report on a large shareholding
Takeda Pharmaceutical: Takeda Pharmaceutical announced the Phase III topline results of Soticlestat (TAK-935) for patients with Dravet syndrome and Lennox-Gastaut syndrome.
Takeda Pharmaceutical: Topline results of the phase 3 clinical trial of Soticlestat (TAK-935) targeting patients with Dravet syndrome and Lennox-Gastaut syndrome.
Takeda Pharmaceutical: Issuance of new shares and disposal of treasury shares based on a long-term incentive plan for employees of conglomerates outside Japan.
Takeda Pharmaceutical: Announcements of individual stocks regarding the issuance of new shares and disposal of treasury stock based on the long-term incentive compensation system for overseas employees of our group.
Takeda Pharmaceutical: Supplementary Issuance Registration Documents (Stock Certificates, Corporate Bonds, etc.)
Takeda Pharmaceutical: Regarding the partial correction of the convocation notice for the 148th regular shareholder meeting.
Takeda Pharmaceutical: Partial amendment of the listed matters in the "Notice of the 148th Ordinary Shareholders' Meeting Convening"
Takeda Pharmaceutical: Statement from the Chairman of the Board of Directors of Takeda Pharmaceuticals Sp Adr regarding the ISS voting rights exercise recommendation prior to the 148th regular shareholders' meeting.
Takeda Pharmaceutical: Opinions from Takeda Pharmaceuticals' Chairman of the Board, Akihiko Iijima, regarding the recommended exercise of voting rights by ISS for the 148th regular shareholders' meeting.
Takeda Pharmaceutical: Announcements of individual stocks regarding the pricing of Japan's diversified bonds.
Takeda Pharmaceutical: Announcements of individual stocks regarding the determination of the conditions for yen-denominated hybrid corporate bonds.
Takeda Pharmaceutical: Supplementary Issuance Registration Documents (Stock Certificates, Corporate Bonds, etc.)
Takeda Pharmaceutical: The latest presentation of Phase 2b data for TAK-861 SLEEP 2024 showed clinically significant effects of an oral orexin agonist in NT1.
Analysis
Price Target
No Data
